Jounce Therapeutics EPS Ratio 2011-2026 | JNCE

EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.

The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares^[1]

EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.

A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.

EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.

Annual EPS Ratio Jounce Therapeutics

2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-0.99	-1.82	-1.24	1.72	-0.84	-0.57	-11	-23.1	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
1.72	-23.1	-4.73

Quarterly EPS Ratio Jounce Therapeutics

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-0.6	-	-0.72	-	-0.59	-0.08	-0.58	-	-0.73	-0.82	-0.78	-	2.99	-0.21	-0.38	-	-0.23	-0.14	-0.4	-0.29	-0.13	-0.11	-0.02	0.11	0.06	-7.23	-6.81	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
2.99	-7.23	-0.804

References

Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.

EPS Ratio of other stocks in the Biotechnology industry

Issuer	EPS Ratio	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-15.4	-	2.43 %	$ 254 M	Germany
Adverum Biotechnologies ADVM	-6.62	-	-	$ 86.2 M	USA
Acorda Therapeutics ACOR	-204	-	-24.86 %	$ 820 K	USA
Nanobiotix S.A. NBTX	-1.35	$ 30.34	-0.82 %	$ 286 B	France
Allakos ALLK	-2.14	-	-	$ 28.6 M	USA
I-Mab IMAB	-7.66	-	-	$ 866 M	China
Akebia Therapeutics AKBA	-0.02	$ 1.4	-0.71 %	$ 360 M	USA
AlloVir ALVR	-2.85	-	4.14 %	$ 49.1 M	USA
Applied Molecular Transport AMTI	-3.25	-	-	$ 10.1 M	USA
Genfit SA GNFT	1.51	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	-0.26	-	-13.47 %	$ 169 M	France
Applied Therapeutics APLT	-1.42	-	-	$ 8.42 M	USA
Aravive ARAV	-2.1	-	-13.39 %	$ 1.45 M	USA
BioNTech SE BNTX	42.2	$ 95.5	3.83 %	$ 27.2 B	Germany
Can-Fite BioPharma Ltd. CANF	-5.97	$ 2.92	-0.34 %	$ 6.35 B	Israel
Aytu BioScience AYTU	-2.16	$ 2.55	-0.78 %	$ 16 M	USA
Midatech Pharma plc MTP	-31	-	-18.52 %	$ 27.3 M	Britain
AstraZeneca PLC AZN	0.08	-	-	$ 96.9 B	Britain
AVROBIO AVRO	0.27	-	1083.1 %	$ 745 M	USA
Advaxis ADXS	-7.99	-	-9.65 %	$ 45.9 M	USA
Amphastar Pharmaceuticals AMPH	2.1	$ 20.37	-2.4 %	$ 952 M	USA
Brainstorm Cell Therapeutics BCLI	-1.11	-	-2.5 %	$ 5.88 M	USA
Aquestive Therapeutics AQST	-0.78	$ 4.08	-2.16 %	$ 436 M	USA
Ayala Pharmaceuticals AYLA	-2.46	-	-	$ 7.46 M	Israel
Arcutis Biotherapeutics ARQT	-0.13	$ 24.21	-1.47 %	$ 3.08 B	USA
BeiGene, Ltd. BGNE	0.2	-	0.49 %	$ 251 B	Cayman-islands
Aeterna Zentaris AEZS	-0.07	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	-1.91	-	-10.17 %	$ 12.2 K	USA
Celldex Therapeutics CLDX	-3.9	$ 32.24	-4.1 %	$ 2.14 B	USA
Aeglea BioTherapeutics AGLE	-24.9	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	-0.36	-	-	$ 26.5 M	USA
CymaBay Therapeutics CBAY	-0.99	-	-	$ 3.45 B	USA
AIkido Pharma AIKI	-1.57	-	1.93 %	$ 17.4 M	USA
Cabaletta Bio CABA	-2.1	$ 3.13	-1.26 %	$ 315 M	USA
Codiak BioSciences CDAK	-1.7	-	-55.98 %	$ 2.15 M	USA
Aptose Biosciences APTO	-10.4	-	-45.71 %	$ 1.2 M	Canada
Avid Bioservices CDMO	-2.23	-	-	$ 789 M	USA
Cidara Therapeutics CDTX	-26.8	-	-	$ 1.41 B	USA
InflaRx N.V. IFRX	-1.26	$ 1.0	-2.91 %	$ 152 M	Germany
Immutep Limited IMMP	-5.03	$ 0.31	-2.52 %	$ 1.08 B	Australia
Akero Therapeutics AKRO	-3.75	-	-	$ 3.67 B	USA
Checkpoint Therapeutics CKPT	-1.42	-	-	$ 169 M	USA
CureVac N.V. CVAC	-2.21	-	-	$ 867 M	Germany
Concert Pharmaceuticals CNCE	-2.33	-	-	$ 401 M	USA
Akari Therapeutics, Plc AKTX	-0.09	$ 3.83	-2.3 %	$ 258 B	Britain
Akouos AKUS	-2.52	-	0.23 %	$ 488 M	USA
Celsion Corporation CLSN	-6.83	-	-6.63 %	$ 13.9 M	USA